J.J.C. declares funding from the National Health and Medical Research Council and Wellcome Trust. S.B. declares peer‐reviewed research funding from CIHR; research support, KT, contract, investigator‐initiated trial from Diamentis and Otsuka; consultant‐advisory board membership for Abbvie, Boheringer, Janssen‐Ortho, Lundbeck, Otsuka, Sunovion, and Takeda; Speaker Bureau for Abbvie, Janssen‐Ortho, Lundbeck, Otsuka, Sunovion; and board member of Relief (myRelief.ca) (pro bono). L.B.A. discloses funding from NIMH R01 126,911. B.E. discloses funding from Agence Nationale de Recherche, Fondation Fondamental, and Sanofi. P.A.G. discloses payment or honoraria from Arrow, Biocodex, Di&Care, Idorsia, Janssen‐Cilag, Jazz pharmaceuticals, Myndblue, and Pharmanovia; B.C.M.H. discloses a ZonMw Postdoc Fellowship (Netherlands Organisation for Health Research and Development; grant number 636320010); LivaNova Investigator Initiated Research grant; Health Holland Public Private Partnership allowance; and payment or honoraria from WAD Cursus (https://www.wadcursus.nl). T.E.G.H. discloses payment for lectures on chronotherapies fort the specialisation program for psychiatrists, Forde Health Trust, Norway (2024) and Stavanger Health Trust, Norway (2023); is a member of the Scientific advisory board for Good Light Group; and donation of blue blocking glasses from Melamedic.dk and Somnoblue for use in research; R.W.L. discloses grants/contracts from BC Leading Edge Endowment Fund, Brain Canada, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Grand Challenges Canada, Healthy Minds Canada, Janssen, Michael Smith Foundation for Health Research, MITACS, Ontario Brain Institute, Unity Health, Vancouver Coastal Health Research Institute, VGH‐UBCH Foundation; royalties or licences from Cambridge University Press, Oxford University Press; payment or honoraria from Carnot, Canadian Medical Protective Association, Lundbeck, Neurotorium, Otsuka, Shanghai Mental Health Center; participation on a DSMB or Advisory Board for AbbVie, Bausch, and Otsuka; and leadership or fiduciary role for Asia‐Pacific Economic Cooperation, Canadian Network for Mood and Anxiety Treatments, CB Solutions, and Genome BC. L.P. discloses consulting fees, payment or honoraria, and participation on a DSMB or advisory board for Bruno, Idorsia, Italfarmaco, Fidia, Neopharmed Gentili, Pfozer, Sanofi, Pharmanutra, and Viatris. J.P. discloses royalties or licences from McGraw‐Hill and W.W. Norton & Co. R.J.P. discloses grants from Wellcome Trust, Health Research Council of New Zealand, Canterbury Medical Research Foundation, and Lotteries Health NZ; support for attending meetings and/or travel from Lundbeck Australia and Servier Australia; and provision of software from SBT Pro. E.F.H.S. discloses support for attendings meetings/travel as a board member of International Society for Bipolar Disorders (ISBD); and leadership or fiduciary roles for ISBD, American Society for Clinical Psychopharmacology, American Association of Chairs of Departments of Psychiatry, and National Network of Depression Centers. E.F.H.S. discloses grants or contracts from National Institute of Mental Health, National Science Foundation, and American Foundation for Suicide Prevention; consulting fees from Mediflix, Postgrad Physician Press, Intracellular Therapies; payment or honoraria from WebMD/Medscape and Clinical Education Alliance; support for attending meetings and/or travel from ISBD; participation on a DSMB or advisory board for grants R01 MH125155 and R01 MH109662; leadership or fiduciary roles for ISBD, American Society for Clinical Psychopharmacology, International Society of Interpersonal Psychotherapy, and Depression and Bipolar Support Alliance; and other financial or non‐financial interests for American Journal of Psychotherapy (Editor‐in‐Chief), UpToDate/Wolters Kluwer (royalties), and American Psychiatric Association (royalties). I.B.H. discloses grants from National Health and Medical Research Council; consulting fees as an advisory board member for Janssen Cilag; payment or honoraria from Janssen Cilag; leadership or fiduciary role for the Australian Department of Health; and Chief Scientific Advisor to, and a 3.2% equity shareholder in, InnoWell Pty Ltd. The other authors declare no conflicts of interest.
PubMed
